198 related articles for article (PubMed ID: 21747703)
1. Sulfotyrosine recognition as marker for druggable sites in the extracellular space.
Ziarek JJ; Heroux MS; Veldkamp CT; Peterson FC; Volkman BF
Int J Mol Sci; 2011; 12(6):3740-56. PubMed ID: 21747703
[TBL] [Abstract][Full Text] [Related]
2. Differences in Sulfotyrosine Binding amongst CXCR1 and CXCR2 Chemokine Ligands.
Moussouras NA; Getschman AE; Lackner ER; Veldkamp CT; Dwinell MB; Volkman BF
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28869519
[TBL] [Abstract][Full Text] [Related]
3. Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12).
Veldkamp CT; Seibert C; Peterson FC; Sakmar TP; Volkman BF
J Mol Biol; 2006 Jun; 359(5):1400-9. PubMed ID: 16725153
[TBL] [Abstract][Full Text] [Related]
4. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.
Ziarek JJ; Liu Y; Smith E; Zhang G; Peterson FC; Chen J; Yu Y; Chen Y; Volkman BF; Li R
Curr Top Med Chem; 2012; 12(24):2727-40. PubMed ID: 23368099
[TBL] [Abstract][Full Text] [Related]
5. The evolution and functional characterization of CXC chemokines and receptors in lamprey.
Sun Z; Qin Y; Liu D; Wang B; Jia Z; Wang J; Gao Q; Zou J; Pang Y
Dev Comp Immunol; 2021 Mar; 116():103905. PubMed ID: 33164777
[TBL] [Abstract][Full Text] [Related]
6. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.
Ziarek JJ; Getschman AE; Butler SJ; Taleski D; Stephens B; Kufareva I; Handel TM; Payne RJ; Volkman BF
ACS Chem Biol; 2013 Sep; 8(9):1955-63. PubMed ID: 23802178
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1.
Millard CJ; Ludeman JP; Canals M; Bridgford JL; Hinds MG; Clayton DJ; Christopoulos A; Payne RJ; Stone MJ
Structure; 2014 Nov; 22(11):1571-81. PubMed ID: 25450766
[TBL] [Abstract][Full Text] [Related]
8. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.
Wedemeyer MJ; Mahn SA; Getschman AE; Crawford KS; Peterson FC; Marchese A; McCorvy JD; Volkman BF
J Biol Chem; 2020 Oct; 295(40):13927-13939. PubMed ID: 32788219
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
10. CCR7 Sulfotyrosine Enhances CCL21 Binding.
Phillips AJ; Taleski D; Koplinski CA; Getschman AE; Moussouras NA; Richard AM; Peterson FC; Dwinell MB; Volkman BF; Payne RJ; Veldkamp CT
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841151
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12.
Veldkamp CT; Seibert C; Peterson FC; De la Cruz NB; Haugner JC; Basnet H; Sakmar TP; Volkman BF
Sci Signal; 2008 Sep; 1(37):ra4. PubMed ID: 18799424
[TBL] [Abstract][Full Text] [Related]
12. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
13. Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.
Veldkamp CT; Ziarek JJ; Peterson FC; Chen Y; Volkman BF
J Am Chem Soc; 2010 Jun; 132(21):7242-3. PubMed ID: 20459090
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CXC-type chemokine molecules in early Xenopus laevis development.
Goto T; Michiue T; Ito Y; Asashima M
Int J Dev Biol; 2013; 57(1):41-7. PubMed ID: 23585351
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A
Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506
[TBL] [Abstract][Full Text] [Related]
16. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
[TBL] [Abstract][Full Text] [Related]
17. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
[TBL] [Abstract][Full Text] [Related]
18. Preparation and Analysis of N-Terminal Chemokine Receptor Sulfopeptides Using Tyrosylprotein Sulfotransferase Enzymes.
Seibert C; Sanfiz A; Sakmar TP; Veldkamp CT
Methods Enzymol; 2016; 570():357-88. PubMed ID: 26921955
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Identification of Novel Ligands Targeting Multiple Sites within a Chemokine-G-Protein-Coupled-Receptor Interface.
Smith EW; Nevins AM; Qiao Z; Liu Y; Getschman AE; Vankayala SL; Kemp MT; Peterson FC; Li R; Volkman BF; Chen Y
J Med Chem; 2016 May; 59(9):4342-51. PubMed ID: 27058821
[TBL] [Abstract][Full Text] [Related]
20. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
